BF-200 ALA
Phase 3Small molecule
BF-200 ALA is one of 60 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 3.
2
Indications
6
Total Trials
0
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
95 competitors in Actinic Keratosis
#DrugCompanyPhaseTrials
1Voltaren
CCerimon Pharmaceuticals
Phase 3
Treatment
GSKPhase 3
Ingenol Metabute
LEO PharmaPhase 3
Levulan
BBiomed Industries, Inc.
Phase 2
Generic Ingenol Mebutate
AActavis Inc.
Phase 3
Lanoxin
AAdvanz Pharma
Phase 2
Kenalog
BBassett Healthcare
Phase 2
Ornidyl
UUSWM, LLC (dba US WorldMeds)
Phase 2
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 2
Active Comparator
ModernaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Actinic Keratosis4 trials
Basal Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BF-200 ALA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBiofrontera Bioscience GmbH